These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 32936732)

  • 21. Want to track pandemic variants faster? Fix the bioinformatics bottleneck.
    Hodcroft EB; De Maio N; Lanfear R; MacCannell DR; Minh BQ; Schmidt HA; Stamatakis A; Goldman N; Dessimoz C
    Nature; 2021 Mar; 591(7848):30-33. PubMed ID: 33649511
    [No Abstract]   [Full Text] [Related]  

  • 22. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.
    Cao M; Su X; Jiang S
    Stem Cell Reports; 2021 Mar; 16(3):398-411. PubMed ID: 33691145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Will SARS-CoV-2 variants of concern affect the promise of vaccines?
    Gupta RK
    Nat Rev Immunol; 2021 Jun; 21(6):340-341. PubMed ID: 33927376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of vaccines in the COVID-19 pandemic: what have we learned?
    Krammer F
    Semin Immunopathol; 2024 Jan; 45(4-6):451-468. PubMed ID: 37436465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
    Edwards AM; Baric RS; Saphire EO; Ulmer JB
    Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of SARS-CoV-2 vaccines.
    Barajas-Nava LA
    Bol Med Hosp Infant Mex; 2021; 78(1):66-74. PubMed ID: 33662986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA vaccines against COVID-19: Perspectives and challenges.
    Silveira MM; Moreira GMSG; Mendonça M
    Life Sci; 2021 Feb; 267():118919. PubMed ID: 33352173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.
    Hodgson SH; Mansatta K; Mallett G; Harris V; Emary KRW; Pollard AJ
    Lancet Infect Dis; 2021 Feb; 21(2):e26-e35. PubMed ID: 33125914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.
    Pillet S; Arunachalam PS; Andreani G; Golden N; Fontenot J; Aye PP; Röltgen K; Lehmicke G; Gobeil P; Dubé C; Trépanier S; Charland N; D'Aoust MA; Russell-Lodrigue K; Monjure C; Blair RV; Boyd SD; Bohm RP; Rappaport J; Villinger F; Landry N; Pulendran B; Ward BJ
    Cell Mol Immunol; 2022 Feb; 19(2):222-233. PubMed ID: 34983950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influenza Virus and SARS-CoV-2 Vaccines.
    Sandor AM; Sturdivant MS; Ting JPY
    J Immunol; 2021 Jun; 206(11):2509-2520. PubMed ID: 34021048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.
    Cromer D; Juno JA; Khoury D; Reynaldi A; Wheatley AK; Kent SJ; Davenport MP
    Nat Rev Immunol; 2021 Jun; 21(6):395-404. PubMed ID: 33927374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. After the pandemic: perspectives on the future trajectory of COVID-19.
    Telenti A; Arvin A; Corey L; Corti D; Diamond MS; García-Sastre A; Garry RF; Holmes EC; Pang PS; Virgin HW
    Nature; 2021 Aug; 596(7873):495-504. PubMed ID: 34237771
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2: Unique Challenges of the Virus and Vaccines.
    Mahmoodpoor A; Sanaie S; Samadi P; Yousefi M; Nader ND
    Immunol Invest; 2021 Oct; 50(7):802-809. PubMed ID: 34109900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of COVID-19 vaccines: From clinical trials to real life.
    Deplanque D; Launay O
    Therapie; 2021; 76(4):277-283. PubMed ID: 34049688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.
    Funk CD; Laferrière C; Ardakani A
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33807839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.